Testing of experimental compounds in a relapse model of tuberculosis using granulocyte-macrophage colony-stimulating factor gene-disrupted mice.
This study describes an in vivo model for evaluating the sterilizing activity of compounds against persisting Mycobacterium tuberculosis. The initial treatment with isoniazid and rifampin in granulocyte-macrophage colony-stimulating factor gene-disrupted mice reduced the number of bacteria more than 99% within 3 weeks. A subsequent treatment with individual drugs was performed to assess their activity on the 1% of remaining bacilli and disease relapse.
Woolhiser
Lisa K
LK
Department of Microbiology, Colorado State University, Fort Collins, Colorado 80523, USA.
Hoff
Donald R
DR
Marietta
Karen S
KS
Orme
Ian M
IM
Lenaerts
Anne J
AJ
D000818:Animals; D000995:Antitubercular Agents / Q000627:therapeutic use*; D001407:Bacillus / Q000187:drug effects; D004195:Disease Models, Animal; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000235:genetics*; D008168:Lung / Q000187:drug effects / Q000382:microbiology; D051379:Mice; D008817:Mice, Mutant Strains; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D013154:Spleen / Q000187:drug effects / Q000382:microbiology; D014376:Tuberculosis / Q000188:drug therapy* / Q000235:genetics*
D000995:Antitubercular Agents; D016178:Granulocyte-Macrophage Colony-Stimulating Factor